DUBLIN--(BUSINESS WIRE)--The "Market Spotlight: Idiopathic Pulmonary Fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering.
This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- It is estimated that in 2018, there were 305,450 incident and 940,840 prevalent cases of idiopathic pulmonary fibrosis (IPF) in adults aged 20 years and older worldwide, and forecasts those numbers to increase to 342,000 incident cases and 1.1 million prevalent cases by 2027.
- Roche's Esbriet and Boehringer Ingelheim's Ofev are the only approved drugs for IPF. These drugs are administered via the oral route.
- Industry-sponsored drugs in active clinical development for IPF are spread evenly across Phase I and Phase II, with two drugs in Phase III.
- Therapies in development for IPF focus on a wide variety of targets. The majority of pipeline drugs in development are administered via an oral formulation.
- The only high-impact upcoming event in the IPF space is topline Phase IIa trial results for PLN-74809. The overall likelihood of approval of a Phase I respiratory-other asset is 9%, and the average probability a drug advances from Phase III is 53.8%. Drugs, on average, take 11.3 years from Phase I to approval, compared to 9.5 years in the overall respiratory space.
- There have been 22 licensing and asset acquisition deals involving IPF drugs during 2014-19. The $4,275m global research and development collaboration agreement signed in 2019 between Gilead and Galapagos, pursuant to which Gilead gained access to Galapagos's drug discovery platform and current and future pipeline outside of Europe, was the largest deal.
- The distribution of clinical trials across Phase I-IV indicates that the majority of trials for IPF have been in the early and midphases of development, with 64% of trials in Phase I-II, and 36% in Phase III-IV.
- The US has a substantial lead in the number of IPF clinical trials globally. The UK leads the major EU markets, while Israel has the top spot in Asia.
- Clinical trial activity in the IPF space is dominated by completed trials. Boehringer Ingelheim has the highest number of completed clinical trials for IPF, with 15 trials.
- Boehringer Ingelheim leads industry sponsors with the highest overall number of clinical trials for IPF, followed by Roche.
Key Topics Covered:
- Disease definition
- Patient segmentation
- Risk factors
- Pharmacologic treatment
- Non-pharmacologic treatments
RECENT EVENTS AND ANALYST OPINION
- GLPG1690 for IPF (July 14, 2019)
- BG00011 for IPF (May 23, 2018)
- KD025 for IPF (May 22, 2018)
- Pamrevlumab for IPF (May 21, 2018)
- GLPG1690 for IPF (May 20, 2018)
- PBI-4050 for IPF (May 20, 2018)
- PRM-151 for IPF (May 20, 2018)
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
- BTD Makes Promedior's PRM-151 Stand Out In IPF Race; Will Bristol Bite?
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
- Boehringer Further Buoys IPF Portfolio With Bridge's Autotaxin Inhibitor
- $5bn Galapagos Deal Won't Be Last For Gilead, Says O'Day
- Galapagos Licenses Global Rights To Fibrocor's IPF Program
- TiumBio Inks $74m License With Chiesi For Potential IPF Drug
- Deals Shaping The Medical Industry, October 2018
- United Therapeutics Licenses Rights To Samumed's IPF Candidate
CLINICAL TRIAL LANDSCAPE
- Sponsors by status
- Sponsors by phase
- Recent events
- Prescription information
- Boehringer Ingelheim
- TiumBio Inks
- United Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/3wc14t